Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697239 | 0.95 | PTGER1 (0.93) | PTGER1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5621433 | 0.94 | PTGER1 (0.91) | PTGER1CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL6150685 | 0.94 | PTGER1 (0.82) | PTGER1CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4150319 | 0.93 | PTGER1 (1.00) | PTGER1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4923860 | 0.92 | PTGER1 (0.88) | PTGER1CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4155505 | 0.92 | PTGER1 (0.76) | PTGER1CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4914446 | 0.91 | PTGER1 (0.96) | PTGER1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL13697117 | 0.90 | PTGER1 (0.85) | PTGER1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4154689 | 0.90 | PTGER1 (0.85) | PTGER1CYP2C9CYP2C19CYP3A4TBXA2R | |
| SCHEMBL4150328 | 0.90 | PTGER1 (0.76) | PTGER1CYP2C9CYP2C19CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885CYP2C19 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.